Moderna (MRNA) Change in Accured Expenses (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Accured Expenses data on file, last reported at $26.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 21.21% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 101.77% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 102.56% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $26.0 million, down from $135.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for MRNA reached as high as $654.0 million in Q3 2023 and fell as low as -$618.0 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged $47.2 million across 5 years, with a median of $35.0 million in 2022.
• Across the five-year window, Change in Accured Expenses plunged 2553.33% in 2024 and soared 6350.0% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $339.0 million in 2022, then plunged by 80.24% to $67.0 million in 2023, then soared by 110.45% to $141.0 million in 2024, then declined by 4.26% to $135.0 million in 2025, then slumped by 80.74% to $26.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $26.0 million in Q1 2026, $135.0 million in Q4 2025, and $258.0 million in Q3 2025.